Aptose Biosciences Valuation
| APS Stock | CAD 2.38 0.11 4.85% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Aptose Biosciences shows a prevailing Real Value of C$1.89 per share. The current price of the firm is C$2.38. Our model approximates the value of Aptose Biosciences from analyzing the firm fundamentals such as Return On Equity of -6.94, current valuation of 11.65 M, and Shares Owned By Insiders of 20.24 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Aptose Biosciences' price fluctuation is extremely dangerous at this time. Calculation of the real value of Aptose Biosciences is based on 3 months time horizon. Increasing Aptose Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Aptose Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Aptose Stock. However, Aptose Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.38 | Real 1.89 | Hype 2.38 | Naive 2.28 |
The intrinsic value of Aptose Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Aptose Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Aptose Biosciences helps investors to forecast how Aptose stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Aptose Biosciences more accurately as focusing exclusively on Aptose Biosciences' fundamentals will not take into account other important factors: Aptose Biosciences Total Value Analysis
Aptose Biosciences is presently projected to have takeover price of 11.65 M with market capitalization of 5.79 M, debt of 14.67 M, and cash on hands of 36.37 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Aptose Biosciences fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
11.65 M | 5.79 M | 14.67 M | 36.37 M |
Aptose Biosciences Asset Utilization
One of the ways to look at asset utilization of Aptose is to check how much profit was generated for every dollar of assets it reports. Aptose Biosciences shows a negative utilization of assets of -1.35 percent, losing C$0.0135 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Aptose Biosciences shows how discouraging it operates for each dollar spent on its assets.Aptose Biosciences Ownership Allocation
Aptose Biosciences retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months.Aptose Biosciences Profitability Analysis
Net Loss for the year was (25.43 M) with profit before overhead, payroll, taxes, and interest of 0.About Aptose Biosciences Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Aptose Biosciences. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Aptose Biosciences based exclusively on its fundamental and basic technical indicators. By analyzing Aptose Biosciences's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Aptose Biosciences's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aptose Biosciences. We calculate exposure to Aptose Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Aptose Biosciences's related companies.Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada. APTOSE BIOSCIENCES operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. It employs 22 people.
Other Information on Investing in Aptose Stock
Aptose Biosciences financial ratios help investors to determine whether Aptose Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Aptose with respect to the benefits of owning Aptose Biosciences security.